Prophylactic treatment in hemophilic patients with inhibitors

Abstract

: The development of inhibitors continues to be the most important complication in severe hemophilia A. The management of inhibitor patients revolves around two basic principles: eradication of the inhibitor and management and prevention of bleeding. In this paper, we review the prophylactic treatments carried out in the last two decades with the two available bypassing agents and the results of the clinical trials carried out with the new molecules under investigation or already licensed for the prevention of hemorrhagic episodes in hemophilia, like emicizumab.